Despite Middle East tensions and a sliding Nifty50, India's smallcap stocks have surged up to 56% in two months. While institutional desks ...

Market expert Anand James suggests caution following recent volatility. He notes the Nifty needs to break above 24,140 for a confirmed upsw...

Promoters are showing increased confidence in several Nifty 500 companies. Their shareholding has risen in the March 2026 quarter compared ...

Pharma stocks showed strength on Thursday, defying market weakness. Dr Reddy's Laboratories saw significant gains, fueled by anticipation o...

Amid a sharp market sell-off triggered by Iran war tensions and rising oil prices, marquee investors like Ashish Kacholia, Mukul Agrawal, M...

OneSource Specialty Pharma shares plunged 18% after reporting a net loss of Rs 47 crore for the December quarter, a significant reversal fr...

Arun Kumar, founder of Strides Group and OneSource, has secured ₹1,000 crore by pledging shares. This move refinances existing loans, exten...

Dipan Mehta of Elixir Equities suggests the pharma sector is facing headwinds from potential US tariffs, impacting margins amid strong comp...

Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from selling semaglutide ...

JM Financial initiates a Buy call on OneSource Specialty Pharma, setting a target price of Rs 2,049, driven by its unique CDMO positioning ...

360 ONE Asset has acquired a stake in OneSource Specialty Pharma, a Contract Development and Manufacturing Organization (CDMO), for an undi...

OneSource Specialty Pharma, an associate of Strides Pharma, secured Rs. 801 crore from investors including HBM Healthcare Investments and W...

OneSource, a TPG Growth-backed specialty pharma CDMO, is in talks with investors to raise $200 million. The company, formerly Stelis Biopha...

Strides Pharma Science has received approval from shareholders and secured creditors to create OneSource, a specialty pharma CDMO. The comp...

As per Trendlyne data, the average target price of Strides Pharma is Rs 530, which shows a downside of 2% from the current market prices. T...

Pharmaceutical company Strides Pharma is planning to demerge its contract development and manufacturing services (CDMO) assets into an asso...

Strides Pharma Science on Monday said it would spin off its contract development and manufacturing organisation (CDMO) and soft gelatin bus...